Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Liu, Jie ^a   Song, Bao ^a   Bai, Xueli ^b   Liu, Wenjian ^c   Li, Zengjun ^a   Wang, Jialin ^a   Zheng, Yan ^a   Wang, Zhehai ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c TAISHAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; INTERLEUKIN 10;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER STAGING; CHINESE; CONTROLLED STUDY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; GENOTYPE; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 77955796786     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-456     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
2. McCracken M, Olsen M, Chen MS, Jemal A, Thun M, Cokkinides V, Deapen D, Ward E. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 2007, 57:190-205. 10.3322/canjclin.57.4.190, 17626117.
3. Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T. Clinical and pathological significance of vitaminD receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. Endocr J 2001, 48:543-9. 10.1507/endocrj.48.543, 11789558.
4. Hayes VM, Severi G, Padilla EJ, Eggleton SA, Southey MC, Sutherl RL, Hopper JL, GilesGG. Genetic variants in the vitamin D receptor gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005, 14:997-9. 10.1158/1055-9965.EPI-04-0660, 15824177.
5. Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S, Akao T, Tsuchiya N, Shimoda N, Wada Y, Koizumi A, Chihara J, et al. Association of vitaminD receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res 2000, 60:305-8.
6. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002, 60:78-83. 10.1016/S0090-4295(02)01637-0, 12100928.
7. Huang S, Ullrich SE, Ber-Eli M. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 1999, 19:697-703. 10.1089/107999099313532, 10454339.
8. Fortis C, Foppoli M, Gianotti L, Galli L, Citterio G, Consogno G, Gentilini O, Braga M. Increased interleukin-10 serum levels in patients with solid tumors. Cancer Lett 1996, 104:1-5. 10.1016/0304-3835(96)04213-9, 8640735.
9. Stearns ME, Rhim J, Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 1999, 5:189-96.
10. Kingo K, Ratsep R, Koks S, Karelson M, Silm H, Vasar E. Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility. J Dermatol Sci 2005, 37:111-3. 10.1016/j.jdermsci.2004.10.002, 15659329.
11. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997, 24:1-8.
12. Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001, 166:3915-22.
13. Eskdale J, Gallagher G. A polymorphic dinucleotide repeat in the human IL-10 promoter. Immunogenetics 1995, 42:444-5. 10.1007/BF00179416, 7590988.
14. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis and Rheumatism 1999, 42:1101-8. 10.1002/1529-0131(199906)42:6<1101::AID-ANR6>3.0.CO;2-Y, 10366102.
15. Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, De Marzo AM, Isaacs WB, Drake CG, Shugart YY, Platz EA. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate 2009, 69:874-85. 10.1002/pros.20933, 19267370.
16. Kesarwani P, Ahirwar DK, Mandhani A, Singh AN, Dalela D, Srivastava AN, Mittal RD. IL-10 -1082 G > A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World J Urol 2009, 27:389-96. 10.1007/s00345-008-0361-1, 19145440.
17. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell WM. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002, 62:3369-72.
18. Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K, Tangrea JA. Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 2008, 19:119-24. 10.1007/s10552-007-9077-6, 17999153.
19. Eder T, Mayer R, Langsenlehner U, Renner W, Krippl P, Wascher TC, Pummer K, Kapp KS. Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study. Eur J Cancer 2007, 43:472-5. 10.1016/j.ejca.2006.11.003, 17182240.
20. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, Hsing A, Huang WY, Hayes RB. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006, 66:4525-30. 10.1158/0008-5472.CAN-05-3987, 16618781.
21. Epstein JI, Allsbrook WC, Amin MB, Egevad LL, . ISUP Grading Committee The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005, 29:1228-42. 10.1097/01.pas.0000173646.99337.b1, 16096414, ISUP Grading Committee.
22. Sabin LH, Wittekind C. TNM classification of malignant Tumors 2002, New York: Wiley-Blackwell Press, 6.
23. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Research 2005, 15:97-8. 10.1038/sj.cr.7290286, 15740637.
24. Jun TY, Pae CU, Kim KS, Han H, Serretti A. Interleukin-10 gene promoter polymorphism is not associated with schizophrenia in the Korean population. Psychiatry Clin Neurosci 2003, 57:153-9. 10.1046/j.1440-1819.2003.01095.x, 12667161.
25. Ide A, Kawasaki E, Abiru N, Sun F, Takahashi R, Kuwahara H, Fujita N, Kita A, Oshima K, Sakamaki H, Uotani S, Yamasaki H, et al. Genetic association between interleukin-10 gene promoter region polymorphisms and type 1 diabetes age-at-onset. Hum Immunol 2002, 63:690-5. 10.1016/S0198-8859(02)00417-2, 12121678.
26. Ferlay J, Bocani GLO. Cancer Incidence and Mortality Worldwide 1998, Lyon: IARC Press.
27. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer-Base No 5, version 2.0 2004, Lyon: IARC Press.